Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02592330 · ClinicalTrials.gov registry record · Phase 1

Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft

A Phase 1 study of Limbal Stem Cell Deficiency, sponsored by Massachusetts Eye and Ear Infirmary.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target
1
Study location

NCT02592330 is a Phase 1 study of Limbal Stem Cell Deficiency that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 23 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02592330, a Phase 1 study of Limbal Stem Cell Deficiency, has completed, sponsored by Massachusetts Eye and Ear Infirmary.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.

Interventions

  • PROCEDURE Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft
  • BIOLOGICAL Cultivation of Limbal epithelial cells into a graft
  • PROCEDURE CALEC Transplant

Study Locations (1)

Massachusetts

  • Massachusetts Eye and Ear Infirmary - Boston

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2016-08-01
Est. Completion 2023-03-31
Phase Phase 1

What the Registry Record Tells You About NCT02592330

The ClinicalTrials.gov registry entry for NCT02592330 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts Eye and Ear Infirmary, which has 73 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Limbal Stem Cell Deficiency appearing as the primary indexed condition, and to 3 interventions - of which Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft is the first listed.

NCT02592330 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02592330 about?

NCT02592330 is a clinical study titled "Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft". The main aim of the study is to determine the safety and feasibility of a cultivated autologous limbal epithelial cell (CALEC) transplantation in the treatment of limbal stem cell deficiency.

What is the current status of trial NCT02592330?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-08-01. Estimated completion is 2023-03-31.

What conditions does trial NCT02592330 study?

This clinical trial studies the following conditions: Limbal Stem Cell Deficiency.

What interventions are being tested in trial NCT02592330?

The interventions under investigation include: Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft (PROCEDURE), Cultivation of Limbal epithelial cells into a graft (BIOLOGICAL), CALEC Transplant (PROCEDURE).

Who is sponsoring clinical trial NCT02592330?

This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02592330 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Limbal Stem Cell Deficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.